Semaglutide slows aging in female mice by reducing caloric intake

Semaglutide, a GLP-1 receptor agonist, extended lifespan approximately 15% in aging female mice when administered late in life, achieving this through a 24% reduction in caloric intake. The critical finding lies in whether these gains merely replicate the well-established effects of calorie restriction—improved physiological function, reduced inflammation, diminished cellular senescence, restored neural stem cells—or whether they reveal something distinct about appetite suppression itself. Researchers matched semaglutide treatment directly against controlled calorie restriction in 20-month-old C57BL/6 female mice, confirming that the drug acts as a "calorie restriction mimetic," modulating the genetic regulators of aging and nutrient sensors in functionally identical patterns. The pivotal distinction: semaglutide-treated mice remained metabolically unstressed and hunger-free, whereas calorically restricted mice experienced chronic hunger signaling with its own independent metabolic consequences. While these preclinical findings are confined to rodent models, they raise a clinically tractable hypothesis requiring long-term human trials: if semaglutide genuinely modulates human aging trajectories, it could influence the broad spectrum of age-related diseases by acting on their common upstream driver.